Full Press Release Details
Biogen Idec Researchers Identify Novel Approach for Promoting Remyelination and Inhibiting Autoimmune Activation as Potential Therapeutic Option for Treatment of Multiple Sclerosis.
BIIB
Biogen Idec Researchers Identify Novel Approach for Promoting Remyelination and Inhibiting Autoimmune Activation as Potential Therapeutic Option for Treatment of Multiple Sclerosis
Key Takeaway: Biogen Idec Researchers Identify Novel Approach for Promoting Remyelination and Inhibiting Autoimmune Activation as Potential Therapeutic Option for Treatment of Multiple Sclerosis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis